Xiankangda Life and Obio Biotech Announce Strategic Collaboration Focused on High-Efficiency Gene Delivery to NK Cells

Dec 29, 2023 10:25 CST Updated 10:25

First conda Life Science

Developer of CAR-T Cell Therapies for Solid Tumors

December 27,Shenzhen Xiankangda Life Science Co., Ltd. (hereinafter referred to as "Xiankangda Life") and Obio Technology (Shanghai) Corp., Ltd. (Stock Code: 688238) (hereinafter referred to as "Obio Technology")Shenzhen Xiankangda Life Science Co., Ltd. and Obio Technology (Shanghai) Corp., Ltd. signed a strategic cooperation agreement in Lingang, Shanghai. Ma Liya, Co-founder and CTO of Xiankangda Life, Liu Dong, Quality Director, Wang Zhongsheng, Early R&D Director, Huang Jing, Head of the CAR-NK Platform, Jia Guodong, CEO of Obio Technology, Yin Shan, Vice General Manager, and Wang Yao, Marketing Director, attended the signing ceremony.

Obio Technology (Shanghai) Corp., Ltd. CEO Guodong Jia and Shenzhen Xiankangda Life Science Co., Ltd. Co-founder and CTO Liya Ma Sign Strategic Cooperation Agreement

With the vigorous development of biomedicine, lentiviral vectors have been widely used as a core tool for gene delivery in basic research and clinical treatment due to their safety, stable integration and expression, and ability to carry large gene fragments. Continuous in-depth research by scientists and multiple updates and iterations of lentiviral vectors have laid the foundation for industry development. CAR-NK cell therapy is expected to become another blockbuster product after CAR-T cell therapy. Gene delivery in NK cells is an extremely important part of the CAR-NK production process and a current industry challenge. Solving the problem of efficient lentiviral transduction of NK cells can provide strong support for the development of CAR-NK cell therapy.

In this strategic cooperation, both parties will rely on their respective advantages to conduct in-depth cooperation, focusing on the innovative lentiviral gene delivery vector that efficiently infects NK cells. The cooperation includes but is not limited to the application and commercial promotion of the innovative vector in basic research and drug development, optimization of the production process of the innovative vector, and improvement of its safety, efficacy, and stability. In addition, the two parties will also work together to carry out more technical exchanges in the field of cell therapy, jointly promote the clinical application of cell therapy, and benefit more patients.

Bilateral Exchange and Discussion

Ma Liya, Co-founder and CTO of Shenzhen Xiankangda Life Science Co., Ltd.Shenzhen Xiankangda Life Science Co., Ltd. expressed deep gratitude for the trust and support from Obio Technology (Shanghai) Corp., Ltd., and is delighted to collaborate with Obio Technology to explore possibilities in the life sciences field. Xiankangda Life has been committed to developing cell-based drugs for solid tumor treatment, including CAR-T and CAR-NK. The focus of this collaboration is a lentiviral system specifically targeting NK cells, developed by Xiankangda Life. Xiankangda Life has made significant modifications and optimizations to improve the efficiency of lentiviral infection of NK cells, achieving a breakthrough enhancement. This advancement brings profound implications for NK technology research and drug development. As a leading CDMO company in the industry, Obio Technology boasts exceptional technical expertise and market promotion capabilities. Leveraging the complementary strengths of both parties, this collaboration is expected to bring mutual benefits and make a positive contribution to the entire industry and society.

Group Photo of Participants from Both Sides

Obio Technology (Shanghai) Corp., Ltd. CEO Guodong JiaExpressed delight in reaching a strategic cooperation with Shenzhen Xiankangda Life Science Co., Ltd. Obio Technology (Shanghai) Corp., Ltd. has always focused on the gene and cell therapy field. With the mission of "Empowering gene therapy, safeguarding life and health together," the company has built two core technology clusters around viral vector research and large-scale production process development, continuously addressing unmet customer and patient needs through technical breakthroughs. Since its establishment, Obio Technology has adhered to technological innovation, balancing independent research and external collaboration, constantly seeking innovative technologies to empower industry development. In the future, Obio Technology looks forward to the lentiviral system targeting NK cells developed through this cooperation being widely adopted by more researchers or pharmaceutical companies to maximize its value. Both parties are expected to cooperate sincerely, sparking more collaborative opportunities in the future.

AboutShenzhen Xiankangda Life Science Co., Ltd.

Shenzhen Xiankangda Life Science Co., Ltd. was established in March 2020. Its R&D and production base is located in the Songshan Lake High-Tech Zone, Dongguan. It is a national high-tech enterprise focusing on the research and industrialization of solid tumor cellular immunotherapy. The company leads with independent research and development of CAR-T products and simultaneously deploys cutting-edge international technologies such as CAR-NK and CAR-iT. It has developed three proprietary technology platforms: Trans-CAR, Boost-CAR, and R-Star, and is currently conducting clinical research on solid tumor CAR-T therapies targeting CLDN18.2, GCC, and Nectin-4 at multiple hospitals.

AboutObio Technology

Obio Technology (Shanghai) Corp., Ltd. (Stock Code: 688238), established in 2013, is a biotechnology company focusing on the gene therapy field. It specializes in providing CRO services such as the development of gene therapy vectors and gene function research for fundamental studies in gene therapy. It also offers CDMO services including process development and testing, IND-CMC pharmaceutical research, and GMP production of clinical samples for the R&D of gene therapy drugs, such as recombinant viral vector drugs, oncolytic viruses, and CAR-T cell therapy products. With the mission of "Empowering Gene Therapy, Safeguarding Life and Health," and with a core focus on the R&D and production of gene therapy vectors, the company will adhere to a customer-centric approach and the responsibility of providing professional services. It aims to build an internationally leading CXO enterprise group in gene and cell therapy, accelerating the basic research, drug discovery, pharmaceutical research, clinical trials, and commercialization processes of gene therapy, promoting the development of the gene therapy industry, and benefiting human health!